Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Forns J, Lopez M, Alvararez-Pedrerol M, Julvez J, Sunyer J. Neuropsychological assessment in the BREATHE project. Poster presented at the DOHaD 2012 Satellite Meeting; December 2012. Rotterdam, the Netherlands.
Karve SJ, Panish JM, Dirani RG, Candrilli SD. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med. 2012 Nov 1;3(4):e183-94.
Forsyth B, Fehnel SE, Danchenko N, Franois C, Brevig T. Assessing impacts of major depressive disorder (MDD) on cognitive function. Value Health. 2012 Nov 1;15(7):A341.
Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. Assessing impacts of major depressive disorder on depression. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 1, 2012. Berlin, Germany.
Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. Patient-reported cognitive symptoms and a patient-reported outcome measure of cognitive function in depression. Poster presented at the Annual European College of Neuropsychopharmacology Congress; October 1, 2012.
Zoega H, Rothman KJ, Huybrechts KF, Olafsson O, Baldursson G, Almarsdottir AB, Jonsdottir S, Halldorsson M, Hernández-Díaz S, Valdimarsdottir UA. A population-based study of stimulant drug treatment of ADHD and academic progress in children. Pediatrics. 2012 Jul 1;130(1):e53-62.
Novick D, Montgomery W, Brnabic A, Aguado J, Kadziola Z, Peng X, Brugnoli R, Haro JM. Prognostic implications of somatic symptoms in patients with depression. Results from a three-month, prospective, observational study from Asia. Poster presented at the 28th CINP World Congress of Neuropsychopharmacology; June 3, 2012. Stockholm, Sweden. [abstract] Int J Neuropsychopharmacol. 2012 Jun; 15(1):191. doi: 10.1017/S1461145712000508
Eap CB, Vandenberghe F, Choong E, Saigi-Morgui N, Ambresin AE, von Gunten A, Conus P. Clinical and pharmacogenetic study on psychotropic drug induced weight gain and other metabolic complications in a Swiss psychiatric population. Poster presented at the 2012 World Congress of the International College of Neuropsychopharmacology; June 2012. Stockholm, Sweden. [abstract] Int J Neuropsychopharmacol. 2012 Jun 1; 15(Suppl 1):101. doi: 10.1017/S1461145712000508
Markowitz M, Karve S, Fu D, Lindenmayer J, Wang C, Candrilli S, Alphs L. Assessing medication adherence and health care utilization and cost patterns among hospital discharged patients with schizoaffective disorder. Poster presented at the 2012 American Psychiatric Association Annual Meeting; May 2012.
DiBenedetti DB, Danchenko N, Francois C, Lewis SA, Davis KH, Fehnel SE. Development of a family functioning scale for major depressive disorder. Curr Med Res Opin. 2012 Mar 1;28(3):303-13.
Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, Schneeweiss S. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012 Feb 1;32(1):11-7.
Zimovetz EA, Wolowacz SE, Classi PM, Birt J. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012 Feb 1;10(1):1.
Kitchen H, Rofail D, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther. 2012 Feb;29(2):148-62.
Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012 Jan 1;15(1):55-64.
Vandenberghe F, Choong E, Saigi-Morgui N, Quteineh L, Ambresin AE, von Gunten A, Conus P, Eap CB. Clinical study on psychotropic drug induced weight gain and other metabolic complications in a Swiss psychiatric population. Poster presented at the 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012; 21(Suppl 3):456. doi: 10.1002